A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).
- Resource Type
- Article
- Authors
- Funt, Samuel A; Knezevic, Andrea; Freeman, Benjamin A; Bolos, Mary; Martorana, Victoria; Donoghue, Mark; Khan, Shah; Singh, Harleen; Bromberg, Maria; Quinlan, Colleen; Carousso, Maryann; Jungbluth, Achim A.; Patil, Sujata; Shah, Neil J.; Lee, Chung-Han; McHugh, Deaglan Joseph; Al-Ahmadie, Hikmat A.; Feldman, Darren R.
- Source
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5040-5040, 1p
- Subject
- Language
- ISSN
- 0732183X